• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pfizer (NY:PFE)

    25.75 -0.14 (-0.56%)
    Streaming Delayed Price Updated: 3:26 PM EDT, May 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pfizer

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    3 Blue Chip Dividend Stocks to Buy in June as the Dow Jones Industrial Average Turns 130 ↗
    The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies. 
    Via The Motley Fool
    Topics Artificial Intelligence Economy Stocks
    News headline image
    This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe? ↗
    The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38% ↗
    As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials. 
    Via The Motley Fool
    News headline image
    Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
    The pharma giant is taking steps to expand its portfolio. 
    Via The Motley Fool
    News headline image
    Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1
    As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    What's the Better Dividend Stock Today: AbbVie or Pfizer? ↗
    These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Is Relay Therapeutics a Buy After Promising Trial Results? ↗
    Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy. 
    Via The Motley Fool
    News headline image
    The Most Important Healthcare Stock You're Not Watching ↗
    Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Pediatrics Medicine Market Size, Industry Report By 2035 ↗
    The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts 
    Via Talk Markets
    Topics Economy
    News headline image
    Prediction: Alphabet Will Join the $5 Trillion Club and the Dow Jones Industrial Average in June ↗
    Honeywell is spinning off its aerospace segment, which could trigger a shake-up in the Dow Jones Industrial Average this summer. 
    Via The Motley Fool
    Topics Stocks
    News headline image
    1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
    Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
    Via StockStory
    News headline image
    2 Reasons to Watch PFE and 1 to Stay Cautious
    Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell shor... 
    Via StockStory
    Topics Supply Chain
    News headline image
    The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗
    The market appears to be short-sighted. 
    Via The Motley Fool
    Topics Intellectual Property Stocks
    News headline image
    2 Profitable Stocks Worth Your Attention and 1 We Find Risky
    Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
    Via StockStory
    Topics Energy
    News headline image
    Pfizer Expands Pneumococcal Vaccine Push With New Programs ↗
    Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20. 
    Via Benzinga
    News headline image
    How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise ↗
    The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study. 
    Via Investor's Business Daily
    Topics Stocks
    News headline image
    Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
    From Pfizer Inc.
    Via Business Wire
    News headline image
    3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗
    These stocks could look like steals in a few years. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    CK Life Sciences’ Sequencio Therapeutics Appoints Emily Tan as Chief Operating Officer
    HONG KONG SAR - Media OutReach Newswire - 18 May 2026 - Sequencio Therapeutics, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life... 
    Via MediaOutReach
    News headline image
    Up 231%, Is RTX Proving Why It Was a Mistake for Honeywell to Replace RTX in the Dow Jones Industrial Average? ↗
    Honeywell was added to the Dow for its tech focus and diversification across different end markets. 
    Via The Motley Fool
    Topics Economy Stocks
    News headline image
    BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
    BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a... 
    Via MarketBeat
    News headline image
    Buy, Sell, or Hold Novo Nordisk at $46? ↗
    Can Novo Nordisk thrive under intense competitive pressures? 
    Via The Motley Fool
    News headline image
    My Top 3 Healthcare Stocks for May 2026 ↗
    Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries. 
    Via The Motley Fool
    News headline image
    2 Ways to Play the Big Pharma Patent Cliff ↗
    With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize. 
    Via MarketBeat
    Topics ETFs Intellectual Property
    News headline image
    1 Stock Under $50 to Target This Week and 2 We Avoid
    The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
    Via StockStory
    News headline image
    Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How ↗
    The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
    Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market. 
    Via The Motley Fool
    News headline image
    Valneva Q1 Earnings Call Highlights ↗
    Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme... 
    Via MarketBeat
    Topics Earnings
    News headline image
    These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗
    Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for... 
    Via Benzinga
    News headline image
    3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
    Investors can find much better opportunities. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.